Abetis Tablet

About Abetis 40 mg Tablet

Abetis 40 mg tablet contains Olmesartan Medoxomil, an angiotensin-II receptor blocker used to treat high blood pressure. It works by blocking the action of a substance that narrows blood vessels.

There are 29 brands of Olmesartan Medoxomil listed in Bangladesh. 8 of them have a lower unit price than Abetis. The lowest listed price is Belsar 10 mg Tablet at ৳ 6.00 per unit.

What is Abetis 40 mg Tablet?

Abetis 40 mg is a tablet containing Olmesartan Medoxomil, a medicine that belongs to a class called angiotensin-II receptor blockers (ARBs). It is used to treat hypertension (high blood pressure). It may be prescribed alone or in combination with other blood pressure medicines. Olmesartan works by blocking the effect of angiotensin-II, a natural substance that constricts blood vessels and raises blood pressure. By blocking this effect, the medicine helps blood vessels relax and lowers blood pressure. The doctor decides the appropriate dose and course for each patient.

Uses of Abetis

Abetis 40 mg is used to treat high blood pressure (hypertension) in adults. It can be used alone or together with other medicines that lower blood pressure. Lowering high blood pressure helps to reduce the risk of serious health problems such as heart attack and stroke. Your doctor will determine if this medicine is suitable for you.

How to use Abetis

Take Abetis 40 mg exactly as your doctor prescribes. The dose and how often you take it will be decided by your doctor based on your condition. Swallow the tablet with water. You can take it with or without food, as food does not affect how the medicine is absorbed. Do not change the dose or stop taking it without talking to your doctor first.

Side effects of Abetis

Like all medicines, Abetis 40 mg can cause side effects, although not everyone gets them. Common side effects include back pain, bronchitis, increased creatine phosphokinase, diarrhoea, headache, blood in urine, high blood sugar, high triglycerides, flu-like symptoms, sore throat, runny nose, and sinusitis. Rarely, chest pain, swelling of the ankles or feet, and arthritis may occur. Call your doctor if you experience any side effect that bothers you or does not go away.

Safety and precautions

Before taking Abetis 40 mg, tell your doctor if you are allergic to olmesartan or any of the ingredients. This medicine is not recommended during pregnancy, especially in the second and third trimesters, as it can harm the unborn baby. If you are pregnant or planning to become pregnant, talk to your doctor immediately. It is not known if olmesartan passes into breast milk, so discuss with your doctor if you are breastfeeding. Your doctor may check your kidney function, especially if you have heart failure or kidney problems.

Frequently asked questions

What is Abetis 40 mg used for and what kind of medicine is it?

Abetis 40 mg is used to treat high blood pressure (hypertension). It contains Olmesartan Medoxomil, which belongs to a group of medicines called angiotensin-II receptor blockers (ARBs). It may be used alone or with other blood pressure medicines.

How should I take Abetis 40 mg?

Take Abetis 40 mg exactly as your doctor tells you. The dose and how often you take it will be decided by your doctor. Swallow the tablet with water, with or without food. Do not change your dose or stop taking it without consulting your doctor.

What side effects should I watch for and when should I call the doctor?

Common side effects include back pain, bronchitis, diarrhoea, headache, flu-like symptoms, sore throat, runny nose, and sinusitis. Rarely, chest pain, swelling of the ankles or feet, and arthritis may occur. Call your doctor if any side effect bothers you or does not go away.

What is the price of Abetis 40 mg?

The listed price is ৳ 18.00.

Indications

Abetis tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Pharmacology

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, Kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. An AT 2 receptor is found also in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Olmesartan has more than a 12,500-fold greater affinity for the AT 1 receptor than for the AT 2 receptor. Olmesartan medoxomil does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.

Dosage & Administration

Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.

No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.

Paediatric use: Safety and effectiveness in paediatric patients have not been established.

Interaction

No significant drug interactions were reported in studies in which Abetis was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids. Abetis is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) in patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Abetis, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Abetis and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including Abetis may be attenuated by NSAIDs including selective COX-2 inhibitors.

Contraindications

Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects

Abetis has been evaluated for safety in more than 3825 patients/subjects, including more than 3275 patients treated for hypertension in controlled trials. Treatment with Abetis was well tolerated, with an incidence of adverse reactions similar to placebo. The overall frequency of adverse reactions was not dose related. Analysis of gender, age and race groups demonstrated no differences between Abetis and placebo treated patients. The rate of withdrawals due to adverse reactions in all trials of hypertensive patients was 2.4% of patients treated with Abetis and 2.7% of control patients. In placebo controlled trials, the only adverse reaction that occurred in more than 1% of patients treated with Abetis and at a higher incidence versus placebo was dizziness (3% vs. 1%)

The following adverse reactions occurred in placebo-controlled clinical trials at an incidence of more than 1% of patients treated with Abetis, but also occurred at about the same or greater incidence in patients receiving placebo: back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis and sinusitis. The incidence of cough was similar in placebo (0.7%) and Abetis (0.9%) patients.

Pregnancy & Lactation

When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Precautions & Warnings

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Abetis. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with Abetis.

Overdose Effects

There is no experience of overdose with Abetis. The most likely effects of Abetis overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred. If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Abetis requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.

Storage Conditions

Store in cool & dry place below 30ºC, protect from light & moisture. Keep out of the reach of children.

Alternative brands of Olmesartan Medoxomil

Other brands with the same generic name, cheapest first.

See all 29 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.